Sangamo, Pfizer collaborate to develop zinc finger protein gene therapy for ALS

This article was originally published here

Sangamo Therapeutics and Pfizer have collaborated for the development of a potential gene therapy using zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply